What Does an Ozempic Gastroparesis Warning Mean for Patients in Pennsylvania?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Occupational Exposure Concerns

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. This condition, where stomach emptying slows dangerously, has been linked to GLP-1 medications like Ozempic. Building on decades of medical research into drug-induced gastrointestinal disorders, this page explains what the FDA's warning means for your long-term outlook and what clinical evaluations you should discuss with your doctor.

Bridging to Clinical Evidence: Ozempic and Gastroparesis

Building on the occupational exposure framework, it is crucial to examine the clinical evidence linking Ozempic to gastroparesis. The clinical presentation of gastroparesis involves delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, postprandial fullness, and abdominal pain. Diagnosis is typically confirmed through gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. This condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes. Its pharmacology includes slowing gastric emptying as part of its mechanism to reduce postprandial glucose excursions. This effect is intended to be transient, but in some patients, it may become persistent or severe, contributing to the development of gastroparesis. In clinical trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Warning Adequacy

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors in the gastrointestinal tract, which can inhibit gastric motility and delay emptying. While this effect is part of the intended therapeutic action, prolonged or excessive inhibition may lead to symptomatic gastroparesis. Postmarketing reports have also raised concerns about pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for significant gastric retention associated with these medications. Regarding the adequacy of warnings, the prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and hypersensitivity reactions, but does not explicitly list gastroparesis as a specific adverse effect. Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not provide specific guidance on the risk of gastroparesis or its management. This may be considered a gap in risk communication, as patients and healthcare providers may not be fully aware of the potential for this serious complication.

Statute of Limitations for Ozempic Claims in Pennsylvania

For affected patients in Pennsylvania, settlement-related considerations depend on the statute of limitations for product liability claims. In Pennsylvania, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. The timeline between exposure to Ozempic and documented harm is critical. Patients who developed gastroparesis after starting Ozempic should document the onset of symptoms, the date of diagnosis, and any medical records linking the drug to the condition. The statute of limitations may begin to run from the date of diagnosis or from when the patient became aware of the potential link between Ozempic and gastroparesis. Settlement considerations may include the strength of the evidence linking Ozempic to gastroparesis, the severity of the patient's condition, and the adequacy of the warnings provided by the manufacturer. Patients should consult with a legal professional experienced in pharmaceutical litigation to evaluate their specific circumstances and ensure timely filing of any claims. In summary, the evidence indicates that Ozempic is associated with gastrointestinal adverse reactions, including delayed gastric emptying, which can lead to gastroparesis. The prescribing information does not explicitly warn about this risk, potentially affecting the adequacy of warnings. Patients in Pennsylvania should be aware of the two-year statute of limitations and seek legal advice promptly to protect their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury claims, including product liability cases related to Ozempic, is generally two years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. For gastroparesis allegedly caused by Ozempic, the clock may start from the date of diagnosis or when the patient became aware of the potential link between the drug and the condition. It is crucial to consult with a legal professional promptly to ensure timely filing.

Does Ozempic's prescribing information warn about gastroparesis?

The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, but it does not explicitly list gastroparesis as a specific adverse effect. This omission may be considered a gap in risk communication, as patients and healthcare providers may not be fully aware of the potential for this serious complication. The label does mention hypersensitivity reactions and pulmonary aspiration risks associated with GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.